NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.
Leela Barham ponders the future of VBP in the light of a new PPRS deal between industry and the UK government.
NHS England (NHSE) has just released the first data covering the first quarter of financial year 2013/14 on the Cancer Drug Fund. Leela Barham assesses the results.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva